Platelet Modulation: A Study of Angiogenic and Coagulation Proteins in Patients With Cancer

NCT ID: NCT01148407

Last Updated: 2011-04-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-06-30

Study Completion Date

2013-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Blood samples on persons with cancer will be sampled for angiogenic, metastatic and coagulation proteins.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with a diagnosis of malignancy

Exclusion Criteria

* Patients taking aspirin, NSAIDs, warfarin or platelet inhibitor therapy
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Vermont

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

University of Vermont

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Chris E Holmes, MD PhD

Role: PRINCIPAL_INVESTIGATOR

University of Vermont

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Vermont/Fletcher Allen Health Care

Burlington, Vermont, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Chris E Holmes, MD, PhD

Role: CONTACT

802-656-0302

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Barbara Kelly

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VCC 0806

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pathogenesis of Hematologic Malignancies
NCT01728402 ENROLLING_BY_INVITATION
Tissue Microarray of Hematological Malignancies
NCT04142372 ACTIVE_NOT_RECRUITING
Biology Studies of Hematologic Cancers
NCT00923442 ENROLLING_BY_INVITATION